CD3D (P04234) variants and mutations
CD3D (also known as P04234) is a human protein-coding gene encoding a t-cell surface glycoprotein CD3 delta chain protein. Within the T-cell receptor complex, it transmits antigen-recognition signals into developing and mature T cells. Biallelic loss-of-function variants can cause severe combined immunodeficiency or related T-cell immunodeficiency. This analysis covers 391 CD3D variants and mutations. Of these, 98% have computational variant effect predictions. Disease context includes immunodeficiency 19, plasma cell myeloma, and neoplasm. Example CD3D variants include E2G, E2K, and H3H.
Variant analysis overview
- Gene: CD3D
- Protein: P04234
- UniProt accession: P04234
- Organism: Homo sapiens
- Variants analyzed: 391
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 236 unspecified-consequence records; 1 stop lost; 63 synonymous variants; 72 missense variants; 4 stop-gained variants; 5 in-frame deletions; 9 frameshift variants; 2 splice-region variants; 1 substitution
- Prediction scores: 383 variants have prediction scores (98% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: immunodeficiency 19, plasma cell myeloma, neoplasm, diffuse large B-cell lymphoma, follicular lymphoma, acute lymphoblastic leukemia, small cell lung carcinoma, Ascites, B-cell acute lymphoblastic leukemia, T-B+ severe combined immunodeficiency, T-B- severe combined immunodeficiency, immunodeficiency 104.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 1 domains; 4 post-translational modification sites.
- Structural context: 124 variants have structural context.
- PTM context: 10 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable CD3D variants
Examples include E2G, E2K, H3H, H3N, S4N, T5M, L7F, S8P. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- E2G (p.Glu2Gly), ExAC rs777623971, TOPMed rs777623971, gnomAD rs777623971, REVEL 0.16, CADD 22.30
- E2K (p.Glu2Lys), Ensembl rs866614844
- H3H (p.His3His), gnomAD 11-118340880-A-G, CADD 5.97
- H3N (p.His3Asn), gnomAD 11-118340882-G-T, CADD 1.03
- S4N (p.Ser4Asn), rs1948310582, ClinGen CA382790703, ClinVar RCV002837900, TOPMed rs1948310582, REVEL 0.12, CADD 12.80, Uncertain significance, Immunodeficiency 19
- T5M (p.Thr5Met), rs200390025, ClinGen CA6302031, ClinVar RCV004435450, 1000Genomes rs200390025, REVEL 0.08, CADD 6.84, Likely benign, Inborn genetic diseases
- L7F (p.Leu7Phe), rs1357653391, ClinGen CA382790655, ClinVar RCV001347301, TOPMed rs1357653391, REVEL 0.34, CADD 24.30, Uncertain significance, Immunodeficiency 19
- S8P (p.Ser8Pro), Ensembl rs1948310327
- S8S (p.Ser8Ser), rs536903960, gnomAD 11-118340910-G-A, CADD 4.58
- S8Y (p.Ser8Tyr), gnomAD 11-118340911-G-T, CADD 4.08
- G9D (p.Gly9Asp), cosmic curated COSV52675, ExAC rs781135510, gnomAD rs781135510, REVEL 0.31, CADD 15.40
- L10V (p.Leu10Val), rs758632643, ClinGen CA6302028, ClinVar RCV001365244, ExAC rs758632643, REVEL 0.26, CADD 16.00, Uncertain significance, Immunodeficiency 19
- V11L (p.Val11Leu), gnomAD rs1185473088, REVEL 0.04, CADD 0.27
- L12P (p.Leu12Pro), Ensembl rs1948309907
- A13P (p.Ala13Pro), gnomAD rs775716265, REVEL 0.33, CADD 16.20
- T14N (p.Thr14Asn), ExAC rs200847716, gnomAD rs200847716, REVEL 0.02, CADD 12.80, Uncertain significance
- T14S (p.Thr14Ser), rs200847716, ClinGen CA382790557, ClinVar RCV002022756, ExAC rs200847716, REVEL 0.02, CADD 9.19, Uncertain significance, Immunodeficiency 19
- L15F (p.Leu15Phe), TOPMed rs892215583, gnomAD rs892215583, REVEL 0.02, AlphaMissense 0.09
- L15I (p.Leu15Ile), TOPMed rs892215583, gnomAD rs892215583, REVEL 0.04, AlphaMissense 0.33
- L15P (p.Leu15Pro), Ensembl rs1591279555
- L16F (p.Leu16Phe), gnomAD rs1449040308, REVEL 0.21, AlphaMissense 0.70
- S17L (p.Ser17Leu), ExAC rs757319080, gnomAD rs757319080, REVEL 0.07, CADD 13.50
- S17* (p.Ser17Ter), gnomAD 11-118340896-G-T, CADD 8.01
- S17S (p.Ser17Ser), rs1480937309, gnomAD 11-118340898-T-G, CADD 1.03
- S17A (p.Ser17Ala), rs1417615347, gnomAD 11-118340903-A-C, CADD 7.46
- S17P (p.Ser17Pro), gnomAD 11-118340903-A-G, CADD 7.74
- Q18K (p.Gln18Lys), rs141902449, ClinGen CA6302021, ClinVar RCV000651981, 1000Genomes rs141902449, REVEL 0.17, CADD 23.20, Likely benign, Immunodeficiency 19
- Q18P (p.Gln18Pro), ExAC rs753003313, TOPMed rs753003313, gnomAD rs753003313, REVEL 0.29, CADD 22.40
- Q18* (p.Gln18Ter), rs756599356, gnomAD 11-118340876-G-A, CADD 3.00
- V19L (p.Val19Leu), Ensembl rs1948309367
- V19M (p.Val19Met), gnomAD 11-118340870-C-T, CADD 6.39
- V19V (p.Val19Val), rs1197847436, gnomAD 11-118340889-G-A, CADD 7.81
- S20R (p.Ser20Arg), rs529268621, ClinGen CA229522918, ClinVar RCV000815198, TOPMed rs529268621, REVEL 0.09, CADD 5.23, Uncertain significance, Immunodeficiency 19
- S20S (p.Ser20Ser), rs529268621, gnomAD 11-118340589-G-A, CADD 3.47
- P21H (p.Pro21His), rs879255345, ClinGen CA10586005, ClinVar RCV000239301, TOPMed rs879255345, REVEL 0.09, CADD 11.10, Uncertain significance, not specified
- P21L (p.Pro21Leu), NCI-TCGA Cosmic COSV5267, cosmic curated COSV52676, REVEL 0.04, CADD 2.77, Variant assessed as somatic; moderate impact.
- P21A (p.Pro21Ala), rs1349195895, gnomAD 11-118340909-G-C, CADD 5.10
- F22L (p.Phe22Leu), 1000Genomes rs563103670, TOPMed rs563103670, gnomAD rs563103670, REVEL 0.06, CADD 6.79
- F22S (p.Phe22Ser), Ensembl rs2134060028, REVEL 0.08, CADD 0.06
- K23E (p.Lys23Glu), ExAC rs199969175, TOPMed rs199969175, gnomAD rs199969175, REVEL 0.07, CADD 0.10, Uncertain significance
- K23N (p.Lys23Asn), rs370657743, cosmic curated COSV52673, ESP rs370657743, REVEL 0.04, CADD 15.50, Variant assessed as somatic; moderate impact.
- K23Q (p.Lys23Gln), rs199969175, ClinGen CA6301994, ClinVar RCV001874363, ExAC rs199969175, REVEL 0.07, CADD 0.08, Uncertain significance, Immunodeficiency 19
- K23R (p.Lys23Arg), ExAC rs761840740, gnomAD rs761840740, REVEL 0.06, CADD 4.96
- I24T (p.Ile24Thr), gnomAD rs1225419723, REVEL 0.16, CADD 13.30
- I24V (p.Ile24Val), gnomAD 11-118340885-T-C, CADD 6.88
- I24L (p.Ile24Leu), rs950390182, gnomAD 11-118340885-T-G, CADD 6.55
- P25H (p.Pro25His), TOPMed rs1591278393, REVEL 0.08, CADD 0.04
- P25R (p.Pro25Arg), TOPMed rs1591278393, REVEL 0.10, CADD 0.01
- P25L (p.Pro25Leu), gnomAD 11-118340575-G-A, REVEL 0.09, CADD 0.03
- P25S (p.Pro25Ser), gnomAD 11-118340576-G-A, REVEL 0.08, CADD 0.00
- I26T (p.Ile26Thr), rs929117843, ClinGen CA229522883, ClinVar RCV001347266, TOPMed rs929117843, REVEL 0.15, CADD 15.70, Uncertain significance, Immunodeficiency 19
- I26V (p.Ile26Val), rs201374139, ClinGen CA229522885, ClinVar RCV000651982, TOPMed rs201374139, REVEL 0.04, CADD 0.10, Uncertain significance, Immunodeficiency 19
- E27E (p.Glu27Glu), rs144504840, gnomAD 11-118340568-C-T, CADD 2.64
- E28K (p.Glu28Lys), NCI-TCGA Cosmic COSV5267, cosmic curated COSV52676, Variant assessed as somatic; moderate impact.
- E28E (p.Glu28Glu), gnomAD 11-118340565-T-C, CADD 9.62
- L29F (p.Leu29Phe), Ensembl rs1948291259, REVEL 0.04, CADD 0.03
- L29R (p.Leu29Arg), TOPMed rs1948291228, gnomAD rs1948291228, REVEL 0.12, CADD 10.10
- L29V (p.Leu29Val), gnomAD 11-118340564-G-C, REVEL 0.04, CADD 0.01
- D31N (p.Asp31Asn), rs1191172324, ClinGen CA382789706, ClinVar RCV001986602, TOPMed rs1191172324, REVEL 0.29, CADD 23.80, Uncertain significance, Immunodeficiency 19
- R32S (p.Arg32Ser), ExAC rs768551495, gnomAD rs768551495, REVEL 0.06, CADD 7.72
- R32T (p.Arg32Thr), NCI-TCGA Cosmic COSV5267, SIFT 0.08, Variant assessed as somatic; moderate impact.
- R32I (p.Arg32Ile), gnomAD 11-118340554-C-A, REVEL 0.19, CADD 13.10
- F34F (p.Phe34Phe), rs1467779483, gnomAD 11-118340547-A-G, CADD 4.82
- N36I (p.Asn36Ile), ExAC rs746752914, TOPMed rs746752914, gnomAD rs746752914, REVEL 0.09, CADD 0.00
- N36N (p.Asn36Asn), gnomAD 11-118340541-A-G, CADD 0.31
- N36K (p.Asn36Lys), gnomAD 11-118340541-A-T, REVEL 0.10, CADD 0.01
- C37* (p.Cys37Ter), ExAC rs775386500, gnomAD rs775386500, CADD 24.50
- C37C (p.Cys37Cys), rs775386500, gnomAD 11-118340538-G-A, CADD 2.93
- C37F (p.Cys37Phe), gnomAD 11-118340539-C-A, REVEL 0.57, CADD 22.80
- p.Cys9 Pro11del, gnomAD 11-118340907-GGGG, CADD 3.37
- N38D (p.Asn38Asp), rs1346172061, ClinGen CA382789569, ClinVar RCV001052705, gnomAD rs1346172061, REVEL 0.07, CADD 3.58, Uncertain significance, Immunodeficiency 19
- N38K (p.Asn38Lys), rs193284900, ClinGen CA6301987, ClinVar RCV001048157, ClinVar RCV005791989, REVEL 0.17, CADD 6.18, Uncertain significance, Immunodeficiency 19; Inborn genetic diseases
- N38S (p.Asn38Ser), ExAC rs771000136, gnomAD rs771000136, REVEL 0.22, CADD 15.40
- N38N (p.Asn38Asn), rs193284900, gnomAD 11-118340535-A-G, CADD 2.77
- T39A (p.Thr39Ala), TOPMed rs959121453
- T39T (p.Thr39Thr), rs1948290781, gnomAD 11-118340532-G-A, CADD 4.46
- S40A (p.Ser40Ala), gnomAD 11-118340531-TG-T, CADD 16.80
- S40G (p.Ser40Gly), gnomAD 11-118340531-T-C, REVEL 0.08, CADD 7.52
- I41V (p.Ile41Val), rs886047737, ClinGen CA10637744, ClinVar RCV000274343, Ensembl rs886047737, AlphaMissense 0.07, MetaLR 0.11, Uncertain significance, Immunodeficiency 19
- I41T (p.Ile41Thr), gnomAD 11-118340527-A-G, REVEL 0.25, CADD 18.50
- T42I (p.Thr42Ile), ExAC rs777709761, TOPMed rs777709761, gnomAD rs777709761, REVEL 0.11, CADD 0.00
- T42R (p.Thr42Arg), ExAC rs777709761, TOPMed rs777709761, gnomAD rs777709761, REVEL 0.12, CADD 0.00
- T42T (p.Thr42Thr), rs1948290662, gnomAD 11-118340523-T-C, CADD 0.27
- W43* (p.Trp43Ter), rs1591278347, ClinGen CA382789484, ClinVar RCV000796754, Ensembl rs1591278347, CADD 24.70, Pathogenic
- W43G (p.Trp43Gly), NCI-TCGA Cosmic COSV5267, Variant assessed as somatic; moderate impact.
- W43L (p.Trp43Leu), NCI-TCGA TCGA novel, SIFT 0.09, Variant assessed as somatic; moderate impact.
- W43R (p.Trp43Arg), gnomAD 11-118340522-A-G, REVEL 0.20, CADD 0.13
- W43C (p.Trp43Cys), gnomAD 11-118340886-C-A, CADD 1.64
- V44A (p.Val44Ala), gnomAD 11-118340518-A-G, REVEL 0.11, CADD 16.10
- E45G (p.Glu45Gly), gnomAD 11-118340515-T-TC, CADD 17.40
- E45K (p.Glu45Lys), gnomAD 11-118340516-C-T, REVEL 0.10, CADD 2.29
- G46R (p.Gly46Arg), gnomAD rs1444773153, NCI-TCGA Cosmic COSV5267, cosmic curated COSV52673, REVEL 0.44, CADD 23.40, Variant assessed as somatic; moderate impact.
- G46G (p.Gly46Gly), gnomAD 11-118340511-T-C, CADD 6.93
- T47M (p.Thr47Met), rs529884894, ClinGen CA6301985, ClinVar RCV001901327, 1000Genomes rs529884894, REVEL 0.30, CADD 21.10, Uncertain significance, Immunodeficiency 19
- T47T (p.Thr47Thr), rs201021372, gnomAD 11-118340508-C-A, CADD 0.08
- T47A (p.Thr47Ala), gnomAD 11-118340510-T-C, REVEL 0.29, CADD 15.60
- V48L (p.Val48Leu), ExAC rs781625373, TOPMed rs781625373, gnomAD rs781625373, REVEL 0.28, CADD 0.01
- V48M (p.Val48Met), ExAC rs781625373, TOPMed rs781625373, gnomAD rs781625373, REVEL 0.34, CADD 0.04
- G49R (p.Gly49Arg), cosmic curated COSV52674, gnomAD rs1261128177, REVEL 0.24, CADD 16.90
- G49T (p.Gly49Thr), gnomAD 11-118340500-GTTC, CADD 20.00
- G49E (p.Gly49Glu), gnomAD 11-118340503-C-T, REVEL 0.18, CADD 7.59
- T50S (p.Thr50Ser), rs1217732214, ClinGen CA382789393, ClinVar RCV001966803, TOPMed rs1217732214, REVEL 0.23, CADD 0.55, Uncertain significance, Immunodeficiency 19
- T50T (p.Thr50Thr), gnomAD 11-118340499-T-C, CADD 2.48
- L51P (p.Leu51Pro), rs200037447, ClinGen CA6301982, ClinVar RCV001316720, ClinVar RCV004968022, REVEL 0.29, CADD 0.05, Uncertain significance, Immunodeficiency 19; Inborn genetic diseases
- L51R (p.Leu51Arg), gnomAD 11-118340497-A-C, REVEL 0.25, CADD 0.02
- L52L (p.Leu52Leu), rs751800253, gnomAD 11-118340493-G-C, CADD 0.06
- L52F (p.Leu52Phe), gnomAD 11-118340495-G-A, REVEL 0.22, CADD 0.00
- S53L (p.Ser53Leu), gnomAD rs1385094145, REVEL 0.26, CADD 8.54
- D54G (p.Asp54Gly), Ensembl rs1023255562, SIFT 0.32
- D54D (p.Asp54Asp), rs1224759102, gnomAD 11-118340487-G-A, CADD 0.09
- I55L (p.Ile55Leu), rs1313114791, ClinGen CA382789334, ClinVar RCV001863880, TOPMed rs1313114791, REVEL 0.09, CADD 0.14, Uncertain significance, Immunodeficiency 19
- I55N (p.Ile55Asn), NCI-TCGA Cosmic COSV5267, cosmic curated COSV52674, SIFT 1.00, Variant assessed as somatic; moderate impact.
- I55V (p.Ile55Val), gnomAD 11-118340486-T-C, REVEL 0.11, CADD 0.04
- T56A (p.Thr56Ala), gnomAD rs1452219808, REVEL 0.14, CADD 7.12
- T56I (p.Thr56Ile), rs201422803, ClinGen CA229522806, ClinVar RCV002010875, ClinVar RCV005308672, REVEL 0.18, CADD 4.94, Uncertain significance, Immunodeficiency 19; Inborn genetic diseases
- T56R (p.Thr56Arg), rs201422803, ClinGen CA382789313, ClinVar RCV004435451, TOPMed rs201422803, REVEL 0.22, CADD 0.40, Uncertain significance, Inborn genetic diseases
- T56K (p.Thr56Lys), rs766581002, gnomAD 11-118340481-TG-T, CADD 12.70
- L58L (p.Leu58Leu), rs1213352686, gnomAD 11-118340475-C-G, CADD 5.72
- L58V (p.Leu58Val), gnomAD 11-118340477-G-C, REVEL 0.21, CADD 0.75
- D59N (p.Asp59Asn), gnomAD 11-118340474-C-T, REVEL 0.04, CADD 3.42
- L60M (p.Leu60Met), Ensembl rs200462658
- L60L (p.Leu60Leu), gnomAD 11-118340469-C-T, CADD 10.30
- G61E (p.Gly61Glu), rs778408963, NCI-TCGA Cosmic COSV5267, cosmic curated COSV52674, TOPMed rs778408963, AlphaMissense 0.80, MetaLR 0.54, Variant assessed as somatic; moderate impact.
- G61R (p.Gly61Arg), cosmic curated COSV10511, Ensembl rs866317904
- G61G (p.Gly61Gly), gnomAD 11-118340466-T-C, CADD 9.41
- K62N (p.Lys62Asn), gnomAD 11-118340462-GT-G, CADD 22.80
- R63C (p.Arg63Cys), rs149264725, ClinGen CA6301979, cosmic curated COSV52675, ClinVar RCV001320462, REVEL 0.20, CADD 13.30, Uncertain significance, Immunodeficiency 19
- R63H (p.Arg63His), rs374700153, ClinGen CA6301978, ClinVar RCV003189728, ClinVar RCV006561186, REVEL 0.21, CADD 20.60, Uncertain significance, Inborn genetic diseases; Immunodeficiency 19
- R63L (p.Arg63Leu), ESP rs374700153, ExAC rs374700153, TOPMed rs374700153, gnomAD rs374700153, REVEL 0.16, CADD 15.50, Uncertain significance
- R63S (p.Arg63Ser), gnomAD 11-118340462-G-T, REVEL 0.18, CADD 8.01
- I64F (p.Ile64Phe), ExAC rs764812030, gnomAD rs764812030, REVEL 0.17, CADD 13.00
- I64I (p.Ile64Ile), rs1215317466, gnomAD 11-118340457-G-T, CADD 7.67
- L65R (p.Leu65Arg), gnomAD rs1386584482, REVEL 0.21, CADD 16.10
- L65L (p.Leu65Leu), rs1424666193, gnomAD 11-118340456-G-A, CADD 6.74
- D66N (p.Asp66Asn), gnomAD rs1181331750, REVEL 0.47, CADD 25.80
- P67P (p.Pro67Pro), rs761459276, gnomAD 11-118340448-T-G, CADD 11.80
- R68* (p.Arg68Ter), rs111033580, ClinGen CA149740, ClinVar RCV000083294, ClinVar RCV002508775, CADD 34.00, Pathogenic
- R68G (p.Arg68Gly), rs111033580, ClinGen CA382789181, ClinVar RCV002046200, ESP rs111033580, REVEL 0.20, CADD 23.60, Uncertain significance, Immunodeficiency 19
- R68Q (p.Arg68Gln), TOPMed rs199795476, REVEL 0.19, CADD 22.70, Uncertain significance, Inborn genetic diseases
- R68P (p.Arg68Pro), gnomAD 11-118340446-C-G, REVEL 0.30, CADD 24.00
- R68R (p.Arg68Arg), rs111033580, gnomAD 11-118340447-G-T, CADD 9.24
- G69R (p.Gly69Arg), gnomAD rs1188035132, REVEL 0.52, CADD 24.60
- I70M (p.Ile70Met), rs2496872266, ClinGen CA382789152, ClinVar RCV003369078, Likely benign, Inborn genetic diseases
- I70T (p.Ile70Thr), ExAC rs760666412, gnomAD rs760666412, REVEL 0.07, CADD 2.84
- Y71H (p.Tyr71His), rs377725940, ClinGen CA229522748, ClinVar RCV000813305, ESP rs377725940, REVEL 0.45, CADD 24.30, Uncertain significance, Immunodeficiency 19
- Y71Y (p.Tyr71Tyr), rs1948289381, gnomAD 11-118340436-A-G, CADD 3.88
- R72S (p.Arg72Ser), TOPMed rs1948289356, gnomAD rs1948289356, REVEL 0.09, CADD 1.53
- R72T (p.Arg72Thr), gnomAD 11-118340434-C-G, REVEL 0.21, CADD 0.00
- C73Y (p.Cys73Tyr), gnomAD 11-118340431-C-T, REVEL 0.56, CADD 25.10
- N74S (p.Asn74Ser), TOPMed rs960253005, REVEL 0.01, CADD 0.00, Uncertain significance, Immunodeficiency 19; Inborn genetic diseases
- N74N (p.Asn74Asn), rs775134685, gnomAD 11-118340427-A-G, CADD 0.17
- N74H (p.Asn74His), gnomAD 11-118340429-T-G, REVEL 0.02, CADD 0.47
- G75A (p.Gly75Ala), NCI-TCGA TCGA novel, SIFT 0.18, Variant assessed as somatic; moderate impact.
- G75R (p.Gly75Arg), gnomAD rs372979468, REVEL 0.19, CADD 11.40
- T76I (p.Thr76Ile), TOPMed rs1289724465, gnomAD rs1289724465, REVEL 0.04, CADD 11.60, Uncertain significance, Inborn genetic diseases
- T76R (p.Thr76Arg), TOPMed rs1289724465, gnomAD rs1289724465, REVEL 0.07, CADD 10.80
- D77H (p.Asp77His), TOPMed rs1244205888, gnomAD rs1244205888, REVEL 0.07, CADD 6.53
- D77V (p.Asp77Val), TOPMed rs1948289134, SIFT 0.03
- D77D (p.Asp77Asp), rs763052940, gnomAD 11-118340418-A-G, CADD 0.26
- D77E (p.Asp77Glu), gnomAD 11-118340418-A-T, REVEL 0.02, CADD 0.00
- I78M (p.Ile78Met), Ensembl rs2134059783, SIFT 0.27
- I78T (p.Ile78Thr), rs528486045, ClinGen CA6301968, ClinVar RCV002577607, ClinVar RCV004064477, REVEL 0.05, CADD 0.03, Uncertain significance, Inborn genetic diseases; Immunodeficiency 19
- I78V (p.Ile78Val), ExAC rs773529981, TOPMed rs773529981, gnomAD rs773529981, REVEL 0.00, CADD 0.07
- Y79* (p.Tyr79Ter), rs2496872144, ClinGen CA382789090, ClinVar RCV003583847, Pathogenic
- Y79C (p.Tyr79Cys), rs2496872150, ClinGen CA382789092, ClinVar RCV003144718, REVEL 0.08, CADD 7.38, Uncertain significance, Immunodeficiency 19
- Y79H (p.Tyr79His), ExAC rs748182805, gnomAD rs748182805
- Y79del (p.Tyr79del), rs763077739, gnomAD 11-118340411-TGTA, CADD 1.28
- K80M (p.Lys80Met), TOPMed rs1948288932
- K80N (p.Lys80Asn), TOPMed rs1354268332, SIFT 0.38
- K80R (p.Lys80Arg), rs1948288932, ClinGen CA382789084, ClinVar RCV002302997, REVEL 0.04, CADD 2.21, Uncertain significance, Immunodeficiency 19
- D81G (p.Asp81Gly), gnomAD 11-118340407-T-C, REVEL 0.05, CADD 0.01
- D81N (p.Asp81Asn), gnomAD 11-118340408-C-T, REVEL 0.01, CADD 0.10
- K82E (p.Lys82Glu), rs1555119773, ClinGen CA382789071, ClinVar RCV000651984, ClinVar RCV005306115, REVEL 0.02, CADD 0.12, Uncertain significance, Inborn genetic diseases; Immunodeficiency 19
- E83* (p.Glu83Ter), NCI-TCGA TCGA novel, CADD 22.60, Variant assessed as somatic; high impact.
- E83D (p.Glu83Asp), gnomAD rs1948288805, REVEL 0.03, CADD 0.10
- E83G (p.Glu83Gly), rs2496872089, ClinGen CA382789060, ClinVar RCV004435454, REVEL 0.08, CADD 0.00, Uncertain significance, Inborn genetic diseases
- E83K (p.Glu83Lys), rs201889742, ClinGen CA229522683, ClinVar RCV001044691, Ensembl rs201889742, REVEL 0.05, CADD 0.03, Uncertain significance, Immunodeficiency 19
- E83N (p.Glu83Asn), NCI-TCGA TCGA novel, SIFT 0.56, Variant assessed as somatic; high impact.
- E83E (p.Glu83Glu), gnomAD 11-118340400-T-C, CADD 0.52
- S84F (p.Ser84Phe), cosmic curated COSV99416, Ensembl rs998941574, SIFT 0.35
Public CD3D analysis runs
- CD3D analysis run — CD3D (391 variants) — completed 2026-08-22